Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.44
ACRX's Cash to Debt is ranked higher than
74% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ACRX: 3.44 )
ACRX' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 3.44

Equity to Asset 0.61
ACRX's Equity to Asset is ranked higher than
68% of the 450 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ACRX: 0.61 )
ACRX' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.61

-0.01
0.69
F-Score: 4
Z-Score: 5.17
M-Score: 5.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -18.06
ACRX's Operating margin (%) is ranked higher than
59% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. ACRX: -18.06 )
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22   Max: -22.6
Current: -18.06

-1805.22
-22.6
Net-margin (%) -5.42
ACRX's Net-margin (%) is ranked higher than
62% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ACRX: -5.42 )
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09   Max: -79.4
Current: -5.42

-1875.09
-79.4
ROE (%) -2.89
ACRX's ROE (%) is ranked higher than
64% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 5.02 vs. ACRX: -2.89 )
ACRX' s 10-Year ROE (%) Range
Min: -130.03   Max: -43.78
Current: -2.89

-130.03
-43.78
ROA (%) -1.81
ACRX's ROA (%) is ranked higher than
66% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. ACRX: -1.81 )
ACRX' s 10-Year ROA (%) Range
Min: -134.55   Max: -26.84
Current: -1.81

-134.55
-26.84
ROC (Joel Greenblatt) (%) -94.84
ACRX's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. ACRX: -94.84 )
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2973.59   Max: -173.98
Current: -94.84

-2973.59
-173.98
EBITDA Growth (3Y)(%) -68.80
ACRX's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ACRX: -68.80 )
ACRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -65
Current: -68.8

EPS Growth (3Y)(%) -70.00
ACRX's EPS Growth (3Y)(%) is ranked higher than
51% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ACRX: -70.00 )
ACRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -64.9
Current: -70

» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACRX Guru Trades in Q1 2014

Louis Moore Bacon 36,000 sh (New)
» More
Q2 2014

ACRX Guru Trades in Q2 2014

Louis Moore Bacon 50,000 sh (+38.89%)
» More
Q3 2014

ACRX Guru Trades in Q3 2014

Paul Tudor Jones 11,400 sh (New)
Louis Moore Bacon Sold Out
» More
Q4 2014

ACRX Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.50
ACRX's P/B is ranked higher than
61% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. ACRX: 6.50 )
ACRX' s 10-Year P/B Range
Min: 2.16   Max: 78
Current: 6.5

2.16
78
P/S 12.00
ACRX's P/S is ranked higher than
58% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 3.75 vs. ACRX: 12.00 )
ACRX' s 10-Year P/S Range
Min: 7.21   Max: 163
Current: 12

7.21
163
POCF 893.00
ACRX's POCF is ranked higher than
70% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 74.13 vs. ACRX: 893.00 )
ACRX' s 10-Year POCF Range
Min: 541   Max: 913
Current: 893

541
913
EV-to-EBIT -40.94
ACRX's EV-to-EBIT is ranked higher than
57% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 68.02 vs. ACRX: -40.94 )
ACRX' s 10-Year EV-to-EBIT Range
Min: -99.2   Max: -1.1
Current: -40.94

-99.2
-1.1
Current Ratio 8.36
ACRX's Current Ratio is ranked higher than
93% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. ACRX: 8.36 )
ACRX' s 10-Year Current Ratio Range
Min: 0.43   Max: 20.39
Current: 8.36

0.43
20.39
Quick Ratio 8.36
ACRX's Quick Ratio is ranked higher than
94% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ACRX: 8.36 )
ACRX' s 10-Year Quick Ratio Range
Min: 0.43   Max: 20.39
Current: 8.36

0.43
20.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.10
ACRX's Price/Net Cash is ranked higher than
94% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ACRX: 8.10 )
ACRX' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 25
Current: 8.1

2.2
25
Price/Net Current Asset Value 8.10
ACRX's Price/Net Current Asset Value is ranked higher than
91% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ACRX: 8.10 )
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 25
Current: 8.1

2.2
25
Price/Tangible Book 6.60
ACRX's Price/Tangible Book is ranked higher than
71% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 6.96 vs. ACRX: 6.60 )
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 57.94
Current: 6.6

2.08
57.94
Price/Median PS Value 0.30
ACRX's Price/Median PS Value is ranked higher than
98% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. ACRX: 0.30 )
ACRX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 3.82
Current: 0.3

0.17
3.82
Earnings Yield (Greenblatt) -2.40
ACRX's Earnings Yield (Greenblatt) is ranked higher than
64% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ACRX: -2.40 )
ACRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.5   Max: 0
Current: -2.4

-2.5
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceutica Oct 15 2014 
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday,... Mar 04 2015
AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday,... Mar 04 2015
AcelRx upgraded by Mizuho Feb 26 2015
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events Feb 20 2015
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events Feb 20 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 13 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 09 2015
AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference Feb 04 2015
Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection? Jan 15 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 13 2015
AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO Dec 16 2014
ACELRX PHARMACEUTICALS INC Files SEC form 8-K/A, Change in Directors or Principal Officers,... Dec 16 2014
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 08 2014
Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? Dec 08 2014
AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso Dec 02 2014
AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso Dec 02 2014
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action... Nov 20 2014
AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events Nov 20 2014
AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events Nov 20 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK